These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21204590)

  • 21. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
    J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health plan utilization and costs of specialty drugs within 4 chronic conditions.
    Gleason PP; Alexander GC; Starner CI; Ritter ST; Van Houten HK; Gunderson BW; Shah ND
    J Manag Care Pharm; 2013 Sep; 19(7):542-8. PubMed ID: 23964615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of antidepressant prescribing concentration to treatment duration and cost.
    Hodgkin D; Merrick EL; Hiatt D
    J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
    West DS; Johnson JT; Hong SH
    J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
    Harris BN; West DS; Johnson J; Hong SH; Stowe CD
    J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit design innovations to manage specialty pharmaceuticals.
    Stern D
    J Manag Care Pharm; 2008 May; 14(4 Suppl):S12-6. PubMed ID: 18507509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization, Cost, and Pricing Scheme of Compounded Medications for Public Health System Patients: The California Workers' Compensation System, 2011-2013.
    Lin TK; Shoair OA; Tran D; Wilson L
    J Manag Care Spec Pharm; 2019 Jul; 25(7):743-751. PubMed ID: 31232208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Best practices in specialty pharmacy management.
    Patterson CJ
    J Manag Care Pharm; 2013; 19(1):42-8. PubMed ID: 23383699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring economic impact of applying daily average consumption limits.
    Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget Impact Analysis of a Pharmacist-Provided Transition of Care Program.
    Ni W; Colayco D; Hashimoto J; Komoto K; Gowda C; Wearda B; McCombs J
    J Manag Care Spec Pharm; 2018 Feb; 24(2):90-96. PubMed ID: 29384028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacy participation and claim characteristics in the Wisconsin Medicaid Pharmaceutical Care Program from 1996 to 2007.
    Look KA; Mott DA; Leedham RK; Kreling DH; Hermansen-Kobulnicky CJ
    J Manag Care Pharm; 2012 Mar; 18(2):116-28. PubMed ID: 22380471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicare risk programs and pharmacy benefits managers.
    Herzfeld J
    Med Interface; 1996 Dec; 9(12):75-8. PubMed ID: 10172875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication therapy management: 10 years of experience in a large integrated health care system.
    Ramalho de Oliveira D; Brummel AR; Miller DB
    J Manag Care Pharm; 2010 Apr; 16(3):185-95. PubMed ID: 20331323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer-guided academic detailing as part of a drug benefit program.
    Keys PW; Goetz CM; Keys PA; Sterchele JA; Snedden TM; Livengood BH
    Am J Health Syst Pharm; 1995 Oct; 52(20):2199-203; discussion 22034. PubMed ID: 8564590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.